Metformin extended release for treating type 2 diabetes mellitus

Endocrine and metabolic

18 January 2021

Published on 18 Jan 2021
Last Updated on 18 Jan 2021

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing metformin extended release on the Standard Drug List (SDL) for treating type 2 diabetes mellitus because of limited clinical need and unfavourable cost-effectiveness compared with metformin immediate release.

Metformin extended release for treating type 2 diabetes mellitus (18 Jan 2021) [PDF, 44 KB]